Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183729 | 0.81 | LMNA (0.42) | CNR2FFAR2PSEN1PSEN2APH1B | |
| SCHEMBL18469870 | 0.79 | CNR2 (0.36) | CNR2FFAR2PSEN1PSEN2APH1B | |
| SCHEMBL18355264 | 0.77 | KDR (0.44) | — | |
| SCHEMBL12143895 | 0.76 | MAPK14 (0.38) | CNR2FFAR2PSEN1PSEN2APH1B | |
| SCHEMBL12754630 | 0.76 | LIMK1 (0.37) | CNR2FFAR2PSEN1PSEN2APH1B | |
| SCHEMBL22522895 | 0.75 | CNR2 (0.36) | CNR2FFAR2PSEN1PSEN2APH1B | |
| SCHEMBL12754631 | 0.73 | LIMK1 (0.50) | — | |
| SCHEMBL16662495 | 0.73 | CNR2 (0.41) | CNR2FFAR2PSEN1PSEN2APH1B | |
| SCHEMBL179490 | 0.73 | CCNE1 (0.52) | CNR2FFAR2 | |
| SCHEMBL13437913 | 0.72 | CDK2 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | CNR2 3248/4885FFAR2 4237/4885PSEN1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.